Skip to main content
BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. logo

BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. — Investor Relations & Filings

Ticker · 300289 ISIN · CNE100001C22 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,949 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300289

About BEIJING LEADMAN BIOCHEMISTRY CO.,LTD.

https://www.leadmanbio.com

Beijing Leadman Biochemistry Co., Ltd. specializes in the research, development, manufacturing, and distribution of in-vitro diagnostic (IVD) solutions. The company’s core portfolio includes a wide range of clinical chemistry reagents, chemiluminescence immunoassay kits, and automated diagnostic instruments. These products support various medical testing areas, such as liver and kidney function, lipid profiles, and cardiac markers. By providing integrated systems that combine high-performance reagents with specialized hardware, the company serves hospitals, clinical laboratories, and medical institutions. Its operations focus on delivering precise and efficient diagnostic tools to enhance clinical decision-making and patient care.

Recent filings

Filing Released Lang Actions
关于公司产品获得IVDR CE认证的公告
Regulatory Filings Classification · 92% confidence The document is an official company announcement regarding two biochemical reagent products obtaining EU IVDR CE certification. This is a regulatory compliance update about product approvals, not a financial report, management change, or capital transaction. It does not contain financial statements or voting results. It fits the “Regulatory Filings” fallback category for general compliance or regulatory announcements.
2026-05-21 Chinese
关于使用闲置自有资金进行委托理财的进展公告
Regulatory Filings Classification · 95% confidence The document is a progress announcement regarding the company's use of idle funds for entrusted financial management, detailing recent transactions, risk analysis, and control measures. It is a specific update on financial activities rather than a full financial report or earnings release. The document length is short (1810 characters) and it is an announcement of progress rather than a comprehensive report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure about financial management activities that does not fit other specific categories.
2026-05-07 Chinese
关于召开2025年度股东会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2025 Annual General Meeting (AGM) of Beijing Leadman Biochemical Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on (including the 2025 annual report and financial statements), registration details, and attachments such as proxy forms and voting instructions. The document does not contain the actual annual report or financial statements but rather serves as an official notification to shareholders about the AGM and the matters to be discussed and voted upon. The document length is 4349 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the definition of AGM Information (AGM-R) rather than the Annual Report (10-K) or other categories.
2026-03-30 Chinese
2025年度非经营性资金占用及其他关联资金往来情况的专项审核说明
Regulatory Filings
2026-03-30 Chinese
2025年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the year 2025, prepared by Beijing Leadman Biochemical Co., Ltd. It includes specific financial figures related to related party transactions, balances, and accounting subjects. The content is financial in nature but does not represent a full annual or interim report, nor is it an announcement or certification. It is a detailed financial disclosure related to related party transactions, which typically falls under Regulatory Filings (RNS) as it does not fit the definitions of other specific report types such as Annual Report, Interim Report, or Audit Report. The document length is 2501 characters, which is relatively short and focused on a specific financial disclosure rather than a comprehensive report.
2026-03-30 Chinese
2025年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2025 年度董事会工作报告" which translates to "2025 Annual Board of Directors Work Report". It details the board's activities, meetings, resolutions, and plans for the next year. It includes financial performance summaries, governance activities, committee work, and strategic plans. The document is about the board's work report for the year 2025, which is a management report explaining company operations, governance, and outlook rather than a full annual report or financial statements. It is not a call transcript, earnings release, or audit report. It is a detailed management report from the board, consistent with the category "Management Reports (MDA)". The document length (5841 characters) supports it being a substantive report rather than a brief announcement or certification. Therefore, the best classification is MDA with high confidence.
2026-03-30 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.